News
DMAC
2.515
+5.23%
0.125
Weekly Report: what happened at DMAC last week (0415-0419)?
Weekly Report · 11h ago
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
NASDAQ · 4d ago
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Inspire Medical Systems (INSP) and Maravai Lifesciences Holdings (MRVI)
TipRanks · 4d ago
DIAMEDICA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN RELAUNCH OF ITS PIVOTAL PHASE 2/3 REMEDY2 TRIAL OF DM199 FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE
Reuters · 5d ago
Weekly Report: what happened at DMAC last week (0408-0412)?
Weekly Report · 04/15 09:49
Diamedica Therapeutics Updates SEC Filing
TipRanks · 04/10 21:37
Weekly Report: what happened at DMAC last week (0401-0405)?
Weekly Report · 04/08 09:51
Weekly Report: what happened at DMAC last week (0325-0329)?
Weekly Report · 04/01 09:51
Weekly Report: what happened at DMAC last week (0318-0322)?
Weekly Report · 03/25 09:52
DiaMedica Therapeutics files for $100M mixed securities shelf
DiaMedica Therapeutics filed a prospectus related to the offer and sell of $100M mixed securities shelf. This prospectus is not an offer to sell. DiaMedica filed for $100m mixed securities shelf. The company is a biopharmaceutical company.
Seeking Alpha · 03/21 20:55
Diamedica Therapeutics Price Target Cut to $8.00/Share From $11.00 by Craig-Hallum
Dow Jones · 03/21 18:41
Diamedica Therapeutics Is Maintained at Buy by Craig-Hallum
Dow Jones · 03/21 18:41
Craig-Hallum Maintains Buy on DiaMedica Therapeutics, Lowers Price Target to $8
Benzinga · 03/21 18:31
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)
3 analysts have maintained Buy ratings on Diamedica Therapeutics, Gossamer Bio and Vor Biopharma. The Healthcare sector has 3 of the top 10 most bullish stocks on The Street. The 3 stocks have a combined market value of $1.2 billion.
TipRanks · 03/21 13:00
Diamedica Therapeutics Price Target Cut to $6.00/Share From $7.00 by Oppenheimer
Dow Jones · 03/21 12:53
Oppenheimer Reiterates Outperform on DiaMedica Therapeutics, Lowers Price Target to $6
Benzinga · 03/21 12:43
Analysts Conflicted on These Healthcare Names: Diamedica Therapeutics (DMAC), Design Therapeutics (DSGN) and MiMedx Group (MDXG)
TipRanks · 03/20 12:50
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
DiaMedica Therapeutics reported earnings per share of -14 cents. The company did not report any revenue for the quarter. This met the analyst estimate for EPS of -13 cents. It is not known if the company will report earnings for the second quarter.
Investorplace · 03/20 01:53
Recap: DiaMedica Therapeutics Q4 Earnings
DiaMedica Therapeutics reported its Q4 earnings on March 19. The company missed its earnings estimate by 0.0%. The company's revenue was down $0 from the same period last year. DiaMedicaTherapeutics is expected to report its earnings on Tuesday.
Benzinga · 03/19 21:25
DiaMedica Therapeutics FY23 EPS $(0.60) Vs $(0.52) YoY; $53M Cash With Runway To 2026
Research and development expenses increased to $13.1 million for the year ended December 31, 2023. The increase was driven principally by costs incurred for the in-use studies performed to address the previous clinical hold on the Company's ReMEDy2 AIS trial. Other income, net, was $1.9 million. General and administrative expenses were $8.2 million.
Benzinga · 03/19 20:31
More
Webull provides a variety of real-time DMAC stock news. You can receive the latest news about Diamedica Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.